Toronto General Research Institute, University Health Network, Toronto, Canada.
Cancer Lett. 2010 Nov 1;297(1):126-36. doi: 10.1016/j.canlet.2010.05.005. Epub 2010 May 26.
gammadelta T cells can be an option for adoptive immunotherapy of cancer. The major obstacle to clinical application of gammadelta T cells is their low number and lack of a reliable method to expand them consistently and efficiently. We were able to expand gammadelta T cells with high purity in all donors regardless of their starting repertoire of gammadelta T cells. These ex vivo expanded gammadelta T cells are in early differentiation stage, can efficiently kill various tumors and inhibit growth of human lung cancer xenografts. This new approach for ex vivo expansion of human gammadelta T cells will open new horizons for clinical use of these cells.
γδ T 细胞可以作为癌症过继免疫疗法的一种选择。γδ T 细胞临床应用的主要障碍是其数量少，且缺乏一致、高效的扩增方法。我们能够在所有供者中以高纯度扩增 γδ T 细胞，而与他们 γδ T 细胞的初始库无关。这些体外扩增的 γδ T 细胞处于早期分化阶段，能够有效地杀伤各种肿瘤，并抑制人肺癌异种移植物的生长。这种体外扩增人 γδ T 细胞的新方法将为这些细胞的临床应用开辟新的前景。
